Acrivon Therapeutics, Common Stock Market Value
| ACRV Stock | 7.16 0.61 9.31% |
| Symbol | Acrivon |
Acrivon Therapeutics, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics,. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.24) | Return On Equity (0.38) |
The market value of Acrivon Therapeutics, is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics,'s market value can be influenced by many factors that don't directly affect Acrivon Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Acrivon Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acrivon Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acrivon Therapeutics,.
| 01/31/2024 |
| 11/26/2024 |
If you would invest 0.00 in Acrivon Therapeutics, on January 31, 2024 and sell it all today you would earn a total of 0.00 from holding Acrivon Therapeutics, Common or generate 0.0% return on investment in Acrivon Therapeutics, over 300 days. Acrivon Therapeutics, is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Acrivon Therapeutics, is entity of United States More
Acrivon Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acrivon Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acrivon Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 22.84 | |||
| Value At Risk | (7.65) | |||
| Potential Upside | 7.66 |
Acrivon Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acrivon Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acrivon Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Acrivon Therapeutics, historical prices to predict the future Acrivon Therapeutics,'s volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.18) |
Acrivon Therapeutics, Backtested Returns
Acrivon Therapeutics, secures Sharpe Ratio (or Efficiency) of -0.0743, which signifies that the company had a -0.0743% return per unit of risk over the last 3 months. Acrivon Therapeutics, Common exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Acrivon Therapeutics,'s Standard Deviation of 4.2, mean deviation of 2.86, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.79, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acrivon Therapeutics, will likely underperform. At this point, Acrivon Therapeutics, has a negative expected return of -0.32%. Please make sure to confirm Acrivon Therapeutics,'s total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Acrivon Therapeutics, performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.18 |
Very weak predictability
Acrivon Therapeutics, Common has very weak predictability. Overlapping area represents the amount of predictability between Acrivon Therapeutics, time series from 31st of January 2024 to 29th of June 2024 and 29th of June 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acrivon Therapeutics, price movement. The serial correlation of 0.18 indicates that over 18.0% of current Acrivon Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.18 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.66 |
Acrivon Therapeutics, lagged returns against current returns
Autocorrelation, which is Acrivon Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Acrivon Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Acrivon Therapeutics, returns to help us make a trade decision. For example, suppose you find that Acrivon Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Acrivon Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Acrivon Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Acrivon Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Acrivon Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Acrivon Therapeutics, Lagged Returns
When evaluating Acrivon Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Acrivon Therapeutics, stock have on its future price. Acrivon Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Acrivon Therapeutics, autocorrelation shows the relationship between Acrivon Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Acrivon Therapeutics, Common.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.